Advanced search
Publication Cover
Expert Review of Anti-infective Therapy Volume 8, 2010 - Issue 4
Submit an article Journal homepage
374
Views
0
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Mortality rates in HIV-infected patients with second failure of antiretroviral therapy are still high: a lesson from NA-ACCORD

Somnuek Sungkanuparph Associate Professor, Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, 10400, Thailand. [email protected]
Pages 371-373 | Published online: 10 Jan 2014

References

  • Deeks SG, Gange SJ, Kitahata MM et al. Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin. Infect. Dis.49, 1582–1590 (2009).
  • Gange SJ, Kitahata MM, Saag MS et al. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NAACCORD). Int. J. Epidemiol.36, 294–301 (2007).
  • Mocroft A, Neaton J, Bebchuk J et al.; EuroSIDA Study Group; ESPRIT Study Group. The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. Clin. Trials3, 119–132 (2006).
  • Eg Hansen AB, Gerstoft J, Kirk O et al. Unmeasured confounding caused slightly better response to HAART within than outside a randomized controlled trial. J. Clin. Epidemiol.61, 87–94 (2008).
  • Hordijk-Trion M, Lenzen M, Wijns W et al. Patients enrolled in coronary intervention trials are not representative of patients in clinical practice: results from the Euro Heart Survey on Coronary Revascularization. Eur. Heart J.27, 671–678 (2006).
  • Kitahata MM, Gange SJ, Abraham AG et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N. Engl. J. Med.360, 1815–1826 (2009).
  • Moore RD, Keruly JC, Gebo KA, Lucas GM. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J. Acquir. Immune Defic. Syndr.39, 195–198 (2005).
  • Porter K, Walker S, Hill T et al. Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 cells/mm3. J. Acquir. Immune Defic. Syndr.47, 202–205 (2008).
  • Srasuebkul P, Lim PL, Lee MP et al. Short-term clinical disease progression in HIV-infected patients receiving combination antiretroviral therapy: results from the TREAT Asia HIV observational database. Clin. Infect. Dis.48, 940–950 (2009).
  • Pacheco YM, Jarrín I, Del Amo J et al. Risk factors, CD4 long-term evolution and mortality of HIV-infected patients who persistently maintain low CD4 counts, despite virological response to HAART. Curr. HIV Res.7, 612–619 (2009).
  • Kigozi BK, Sumba S, Mudyope P et al. The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda. AIDS Res. Ther.6, 17 (2009).
  • Brinkhof MW, Boulle A, Weigel R et al.; International Epidemiological Databases to Evaluate AIDS (IeDEA). Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med.6, e1000066 (2009).
  • Sobrino-Vegas P, García-San Miguel L, Caro-Murillo AM et al. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr. HIV Res.7, 224–230 (2009).
  • Chasombat S, McConnell MS, Siangphoe U et al. National expansion of antiretroviral treatment in Thailand, 2000–2007: program scale-up and patient outcomes. J. Acquir. Immune Defic. Syndr.50, 506–512 (2009).
  • Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin. Infect. Dis.44, 447–452 (2007).
  • Zhang F, Dou Z, Ma Y et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann. Intern. Med.151, 241–251 (2009).
  • Malta M, Bastos FI, da Silva CM et al. Differential survival benefit of universal HAART access in Brazil: a nation-wide comparison of injecting drug users versus men who have sex with men. J. Acquir. Immune Defic. Syndr.52, 629–635 (2009).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.